Media headlines about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novo Nordisk A/S earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.7277648181324 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Blog Exposure – Novo Nordisk’s Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes (finance.yahoo.com)
- Novo Nordisk’s once-weekly Type II diabetes med approved in Europe (massdevice.com)
- Novo Nordisk’s Dichotomy Abounds (fool.com)
- Novo Nordisk's Dichotomy Abounds (finance.yahoo.com)
NVO has been the topic of a number of research analyst reports. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, December 6th. Deutsche Bank restated a “buy” rating on shares of Novo Nordisk A/S in a report on Monday, January 8th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a report on Tuesday, January 2nd. JPMorgan Chase & Co. upgraded shares of Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research note on Friday, December 29th. Finally, Morgan Stanley upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $64.00.
Novo Nordisk A/S announced that its Board of Directors has initiated a stock repurchase plan on Thursday, February 1st that allows the company to repurchase outstanding shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.
The firm also recently declared a special dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Monday, March 26th will be paid a $0.8117 dividend. The ex-dividend date is Friday, March 23rd. This represents a yield of 0.96%. Novo Nordisk A/S’s payout ratio is currently 32.28%.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Novo Nordisk A/S (NVO) Stock Price” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-novo-nordisk-a-s-nvo-stock-price.html.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.